Literature DB >> 24050400

Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.

Masahiro Maruyama1, Hitoshi Shimada, Tetsuya Suhara, Hitoshi Shinotoh, Bin Ji, Jun Maeda, Ming-Rong Zhang, John Q Trojanowski, Virginia M-Y Lee, Maiko Ono, Kazuto Masamoto, Harumasa Takano, Naruhiko Sahara, Nobuhisa Iwata, Nobuyuki Okamura, Shozo Furumoto, Yukitsuka Kudo, Qing Chang, Takaomi C Saido, Akihiko Takashima, Jada Lewis, Ming-Kuei Jang, Ichio Aoki, Hiroshi Ito, Makoto Higuchi.   

Abstract

Accumulation of intracellular tau fibrils has been the focus of research on the mechanisms of neurodegeneration in Alzheimer's disease (AD) and related tauopathies. Here, we have developed a class of tau ligands, phenyl/pyridinyl-butadienyl-benzothiazoles/benzothiazoliums (PBBs), for visualizing diverse tau inclusions in brains of living patients with AD or non-AD tauopathies and animal models of these disorders. In vivo optical and positron emission tomographic (PET) imaging of a transgenic mouse model demonstrated sensitive detection of tau inclusions by PBBs. A pyridinated PBB, [(11)C]PBB3, was next applied in a clinical PET study, and its robust signal in the AD hippocampus wherein tau pathology is enriched contrasted strikingly with that of a senile plaque radioligand, [(11)C]Pittsburgh Compound-B ([(11)C]PIB). [(11)C]PBB3-PET data were also consistent with the spreading of tau pathology with AD progression. Furthermore, increased [(11)C]PBB3 signals were found in a corticobasal syndrome patient negative for [(11)C]PIB-PET.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24050400      PMCID: PMC3809845          DOI: 10.1016/j.neuron.2013.07.037

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  27 in total

1.  Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease.

Authors:  Nobuyuki Okamura; Takahiro Suemoto; Shozo Furumoto; Masako Suzuki; Hiroshi Shimadzu; Hiroyasu Akatsu; Takayuki Yamamoto; Hironori Fujiwara; Miyako Nemoto; Masahiro Maruyama; Hiroyuki Arai; Kazuhiko Yanai; Tohru Sawada; Yukitsuka Kudo
Journal:  J Neurosci       Date:  2005-11-23       Impact factor: 6.167

2.  PET of brain amyloid and tau in mild cognitive impairment.

Authors:  Gary W Small; Vladimir Kepe; Linda M Ercoli; Prabha Siddarth; Susan Y Bookheimer; Karen J Miller; Helen Lavretsky; Alison C Burggren; Greg M Cole; Harry V Vinters; Paul M Thompson; S-C Huang; N Satyamurthy; Michael E Phelps; Jorge R Barrio
Journal:  N Engl J Med       Date:  2006-12-21       Impact factor: 91.245

3.  2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients.

Authors:  Yukitsuka Kudo; Nobuyuki Okamura; Shozo Furumoto; Manabu Tashiro; Katsutoshi Furukawa; Masahiro Maruyama; Masatoshi Itoh; Ren Iwata; Kazuhiko Yanai; Hiroyuki Arai
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

4.  Alzheimer's disease. A new take on tau.

Authors:  Jean Marx
Journal:  Science       Date:  2007-06-08       Impact factor: 47.728

Review 5.  Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).

Authors:  Dennis W Dickson; Naomi Kouri; Melissa E Murray; Keith A Josephs
Journal:  J Mol Neurosci       Date:  2011-07-01       Impact factor: 3.444

6.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807.

Authors:  David T Chien; Shadfar Bahri; A Katrin Szardenings; Joseph C Walsh; Fanrong Mu; Min-Ying Su; William R Shankle; Arkadij Elizarov; Hartmuth C Kolb
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Authors:  Henry Engler; Anton Forsberg; Ove Almkvist; Gunnar Blomquist; Emma Larsson; Irina Savitcheva; Anders Wall; Anna Ringheim; Bengt Långström; Agneta Nordberg
Journal:  Brain       Date:  2006-07-19       Impact factor: 13.501

8.  Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography.

Authors:  Jun Maeda; Bin Ji; Toshiaki Irie; Takami Tomiyama; Masahiro Maruyama; Takashi Okauchi; Matthias Staufenbiel; Nobuhisa Iwata; Maiko Ono; Takaomi C Saido; Kazutoshi Suzuki; Hiroshi Mori; Makoto Higuchi; Tetsuya Suhara
Journal:  J Neurosci       Date:  2007-10-10       Impact factor: 6.167

9.  Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies.

Authors:  Paul W Thompson; Liang Ye; Jennifer L Morgenstern; Lucia Sue; Thomas G Beach; Duncan J Judd; Nicholas J Shipley; Vincenzo Libri; Andrew Lockhart
Journal:  J Neurochem       Date:  2009-02-13       Impact factor: 5.372

10.  The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component.

Authors:  William E Klunk; Yanming Wang; Guo-feng Huang; Manik L Debnath; Daniel P Holt; Li Shao; Ronald L Hamilton; Milos D Ikonomovic; Steven T DeKosky; Chester A Mathis
Journal:  J Neurosci       Date:  2003-03-15       Impact factor: 6.167

View more
  271 in total

Review 1.  Suspected non-Alzheimer disease pathophysiology--concept and controversy.

Authors:  Clifford R Jack; David S Knopman; Gaël Chételat; Dennis Dickson; Anne M Fagan; Giovanni B Frisoni; William Jagust; Elizabeth C Mormino; Ronald C Petersen; Reisa A Sperling; Wiesje M van der Flier; Victor L Villemagne; Pieter J Visser; Stephanie J B Vos
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

2.  Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351.

Authors:  Ryuichi Harada; Shozo Furumoto; Tetsuro Tago; Katsutoshi Furukawa; Aiko Ishiki; Naoki Tomita; Ren Iwata; Manabu Tashiro; Hiroyuki Arai; Kazuhiko Yanai; Yukitsuka Kudo; Nobuyuki Okamura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-07-19       Impact factor: 9.236

3.  Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies.

Authors:  Maiko Ono; Naruhiko Sahara; Katsushi Kumata; Bin Ji; Ruiqing Ni; Shunsuke Koga; Dennis W Dickson; John Q Trojanowski; Virginia M-Y Lee; Mari Yoshida; Isao Hozumi; Yasumasa Yoshiyama; John C van Swieten; Agneta Nordberg; Tetsuya Suhara; Ming-Rong Zhang; Makoto Higuchi
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

Review 4.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

5.  Aminothienopyridazines as imaging probes of tau pathology: a patent evaluation of WO2013090497.

Authors:  Carlo Ballatore; Amos B Smith; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Expert Opin Ther Pat       Date:  2014-01-03       Impact factor: 6.674

Review 6.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

7.  Positron emission tomography imaging of tau pathology in progressive supranuclear palsy.

Authors:  Sarah Coakeley; Sang Soo Cho; Yuko Koshimori; Pablo Rusjan; Madeleine Harris; Christine Ghadery; Jinhee Kim; Anthony E Lang; Alan Wilson; Sylvain Houle; Antonio P Strafella
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-22       Impact factor: 6.200

Review 8.  Biomarker modelling of early molecular changes in Alzheimer's disease.

Authors:  Ross W Paterson; Jamie Toombs; Catherine F Slattery; Jonathan M Schott; Henrik Zetterberg
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 9.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

Review 10.  Interactions between Microtubule-Associated Protein Tau (MAPT) and Small Molecules.

Authors:  Jennifer N Rauch; Steven H Olson; Jason E Gestwicki
Journal:  Cold Spring Harb Perspect Med       Date:  2017-07-05       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.